CN109475542A - 用于治疗癌症的组合疗法 - Google Patents

用于治疗癌症的组合疗法 Download PDF

Info

Publication number
CN109475542A
CN109475542A CN201780045352.0A CN201780045352A CN109475542A CN 109475542 A CN109475542 A CN 109475542A CN 201780045352 A CN201780045352 A CN 201780045352A CN 109475542 A CN109475542 A CN 109475542A
Authority
CN
China
Prior art keywords
compound
formula
chemotherapeutant
pharmaceutically acceptable
inv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780045352.0A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·H·布什韦勒
阿努拉德哈·伊伦杜拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
Original Assignee
University of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia Patent Foundation filed Critical University of Virginia Patent Foundation
Publication of CN109475542A publication Critical patent/CN109475542A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201780045352.0A 2016-07-27 2017-07-27 用于治疗癌症的组合疗法 Pending CN109475542A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662367263P 2016-07-27 2016-07-27
US62/367,263 2016-07-27
PCT/US2017/044124 WO2018022855A1 (en) 2016-07-27 2017-07-27 Combination therapies for treating cancer

Publications (1)

Publication Number Publication Date
CN109475542A true CN109475542A (zh) 2019-03-15

Family

ID=61016782

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780045352.0A Pending CN109475542A (zh) 2016-07-27 2017-07-27 用于治疗癌症的组合疗法

Country Status (13)

Country Link
US (1) US11241421B2 (https=)
EP (1) EP3490557B1 (https=)
JP (1) JP2019525924A (https=)
KR (1) KR20190032370A (https=)
CN (1) CN109475542A (https=)
AU (1) AU2017302330A1 (https=)
BR (1) BR112019000049A2 (https=)
CA (1) CA3028461A1 (https=)
EA (1) EA201990395A1 (https=)
IL (1) IL263942A (https=)
MX (1) MX2019000179A (https=)
WO (1) WO2018022855A1 (https=)
ZA (1) ZA201900438B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117567434A (zh) * 2022-08-08 2024-02-20 武汉大学 靶向CBFβ-SMMHC蛋白的PROTAC类化合物及其制备方法与应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021525280A (ja) 2018-05-24 2021-09-24 ユニバーシティ オブ バージニア パテント ファウンデーション がんを治療するための併用療法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372719B1 (en) * 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
US20140243331A1 (en) * 2009-05-13 2014-08-28 University Of Virginia Patent Foundation Inhibitors of inv(16) leukemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643935A (en) 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
WO2006104668A2 (en) 2005-03-11 2006-10-05 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
CA2614324A1 (en) * 2005-07-06 2007-01-18 Kanisa Pharmaceuticals, Inc. Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372719B1 (en) * 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
US20140243331A1 (en) * 2009-05-13 2014-08-28 University Of Virginia Patent Foundation Inhibitors of inv(16) leukemia

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117567434A (zh) * 2022-08-08 2024-02-20 武汉大学 靶向CBFβ-SMMHC蛋白的PROTAC类化合物及其制备方法与应用

Also Published As

Publication number Publication date
MX2019000179A (es) 2019-06-20
ZA201900438B (en) 2019-10-30
JP2019525924A (ja) 2019-09-12
EP3490557A1 (en) 2019-06-05
US11241421B2 (en) 2022-02-08
CA3028461A1 (en) 2018-02-01
KR20190032370A (ko) 2019-03-27
AU2017302330A1 (en) 2019-01-17
US20190343820A1 (en) 2019-11-14
IL263942A (en) 2019-02-28
EA201990395A1 (ru) 2019-07-31
WO2018022855A1 (en) 2018-02-01
EP3490557B1 (en) 2022-09-07
EP3490557A4 (en) 2020-04-01
BR112019000049A2 (pt) 2019-04-02

Similar Documents

Publication Publication Date Title
ES2409755T3 (es) Método para Tratar el Cáncer Utilizando un Agente Anticanceroso Combinado
Ferry et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition.
AU2018288021A1 (en) Use of cannabidiol in the treatment of Tuberous Sclerosis complex
US20070281040A1 (en) Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
US8993587B2 (en) Combination of syrosingopine and mitochondrial inhibitors for the treatment of cancer and immunosuppression
Strimpakos et al. Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?
Galani Combination treatment for glioblastoma with temozolomide, DFMO and radiation
CN109152839A (zh) 双极性反式类胡萝卜素连同化疗和放射治疗在治疗癌症中的用途
KR20240004519A (ko) 면역관문 억제제와 함께 akr1c3-활성화 화합물을 사용하는 병용 요법
Aas et al. Growth inhibition of rat glioma cells in vitro and in vivo by aspirin
CN109475542A (zh) 用于治疗癌症的组合疗法
KR20160032989A (ko) Her-2 표적화 압타머 복합체 및 이의 용도
CN111920788B (zh) 一种抑制脑肿瘤的药物及其应用
Wonders et al. Endurance exercise training preserves cardiac function in rats receiving doxorubicin and the HER-2 inhibitor GW2974
Langevin et al. A phase II trial of rebeccamycin analogue (NSC# 655649) in children with solid tumors: a Children's Oncology Group study
US20210023104A1 (en) Use of ginsenoside m1 for manufacturing medicament for treating oral cancer
Rubie et al. Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours
Kim et al. Celecoxib enhances the radiosensitizing effect of 7-hydroxystaurosporine (UCN-01) in human lung cancer cell lines
Lopez-Iglesias et al. Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone
Jain et al. Carbohydrate kinase inhibition: a promising strategy in cancer treatment
Hua et al. Gs-coupled adenosine receptors differentially limit antigen-induced mast cell activation
HK40003583A (en) Combination therapies for treating cancer
Demirci et al. Long term experience in high grade glial tumors with temozolomide
Staicu et al. Improving the Response of High-Grade Glioma (HGG) Cells to Temozolomide Treatment Through Combination With Imatinib
CA2557857C (en) Cancer treatment with topoisomerase-ii inhibitor, a bis-dioxypiperazine and radiation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40003583

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190315

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40003583

Country of ref document: HK